Design Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

DSGN$10.21+5.6%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Balance Sheets

(in thousands, except share and par value data)

	September 30,	December 31,
	2025	2024
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$15,088	$22,563
Investment securities	190,882	222,914
Prepaid expenses and other current assets	3,059	2,563
Total current assets	209,029	248,040
Property and equipment, net	1,104	1,410
Right-of-use asset, related party	1,637	2,216
Other assets	—	427
Total assets	$211,770	$252,093
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$1,913	$2,186
Accrued expenses and other current liabilities (including related party amounts of $866 and $800 respectively)	9,260	6,276
Total current liabilities	11,173	8,462
Operating lease liability, net, related party	877	1,534
Total liabilities	12,050	9,996
Commitments and contingencies (See Note 8)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized at September 30, 2025 and December 31, 2024; 56,963,757 and 56,754,341 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	6	6
Additional paid-in capital	480,365	468,830
Accumulated deficit	(281,009)	(227,214)
Accumulated other comprehensive income	358	475
Total stockholders’ equity	199,720	242,097
Total liabilities and stockholders’ equity	$211,770	$252,093

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.